Dosing Begins in Phase 1 Trial of FT-7051 for Advanced, Resistant Cancer

Dosing Begins in Phase 1 Trial of FT-7051 for Advanced, Resistant Cancer

285329

Dosing Begins in Phase 1 Trial of FT-7051 for Advanced, Resistant Cancer

Dosing has begun in a Phase 1 clinical trial testing Forma Therapeutics’ investigational therapy FT-7051 in people with metastatic castration-resistant prostate cancer (mCRPC). Recruiting at sites in Arizona and South Carolina, the open-label trial (NCT04575766) is expected to enroll 45 patients who failed to respond to at least one potent anti-androgen treatment. Contact and site information can be found here. “Initiating enrollment in this Phase 1 trial is an important step toward our goal of providing…

You must be logged in to read/download the full post.